A life-changing treatment is now within reach for Australians battling a rare and debilitating disease. But is it accessible to all who need it?
Ultomiris®, a groundbreaking medication developed by Alexion, AstraZeneca Rare Disease, has been listed on the Pharmaceutical Benefits Scheme (PBS) in Australia. This is a significant milestone for those living with generalised myasthenia gravis (gMG), a chronic autoimmune neuromuscular disease that affects muscle function and causes severe weakness.
The announcement, made by Health Minister Mark Butler, brings hope to the estimated 3,000 Australians with gMG, particularly the 80% who are anti-acetylcholine receptor (AChR) antibody positive (Ab+). This condition can strike at any age, but it's most common in women before 40 and men after 60.
But here's where it gets controversial: While Ultomiris® is now available on the PBS for acute, severe gMG cases and as a short-term control option, it's not a one-size-fits-all solution. The treatment is indicated for specific patient groups, including those at high risk of rapid deterioration and those not responding to or intolerant of other therapies.
Leading neurologist and gMG expert, Associate Professor Stephen Reddel, highlights the disease's impact: "Generalised myasthenia gravis can be a debilitating disease, causing severe symptoms that make daily tasks challenging. In severe cases, breathing, swallowing, and body movements can be affected, leading to serious complications."
Susan White, Chairperson of Myasthenia Alliance Australia, expressed relief: "It's a significant day for myasthenia gravis patients, who now have PBS access to this new treatment. We're grateful to the government for making this innovative medicine available."
Nicole Gaupset, General Manager of Alexion Australasia, shared the company's commitment: "We're dedicated to bringing innovation to rare disease patients. It's been a long journey, but we're thrilled that our gMG treatment is now PBS-listed."
A word of caution: Ultomiris® is not without risks. It increases the likelihood of meningococcal infections, which can be life-threatening. Patients must be immunised with meningococcal vaccines at least two weeks before treatment, and healthcare professionals should monitor for early signs of infection.
This treatment is a powerful tool, but it's not a standalone solution. As Associate Professor Reddel advises, patients should discuss all treatment options with their clinicians to find the best approach for their specific needs.
The bigger picture: Alexion, AstraZeneca Rare Disease, has been a pioneer in rare disease research for over 30 years, focusing on the complement system. The company continues to expand globally, aiming to serve more patients worldwide.
What are your thoughts on this development? Do you think the PBS listing of Ultomiris® will significantly improve access to treatment for gMG patients? Share your opinions below, and let's spark a conversation about this important healthcare advancement.
